Alexion Pharmaceuticals has announced financial results for the three and nine months ended September 30, 2014. The company reported net product sales of Soliris® (eculizumab) of $555.1 million in the third quarter of 2014, an increase of 39 percent from the same period in 2013. Revenue performance for the quarter reflected steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment.
Alexion is serving patients with PNH and aHUS in nearly 50 countries. Both PNH and aHUS are severe and life-threatening ultra-rare disorders caused by chronic uncontrolled complement activation.
“In the third quarter of 2014, we served an increasing number of new patients with PNH and aHUS worldwide while simultaneously reaching several significant milestones across our pipeline, including the filing of our NDA for asfotase alfa in Japan and the completion of the juvenile-onset HPP natural history study which enables us to complete our rolling BLA submission in the U.S.,” said Leonard Bell, M.D., Chairman and Chief Executive Officer of Alexion. “Our third quarter performance underscores the significant opportunity we have to serve more patients with PNH and aHUS globally. While we remain focused on our initiatives to reach more patients in our current operations, we are also preparing for the global launch of asfotase alfa in 2015 and advancing our lead development programs as we drive toward as many as seven additional launches through 2018.”
